Biochemical Pharmacology · 2020 · 32 citations · 35 references
MedicineHematologyPharmacologyClinical PharmacologyMolecular PharmacologySignal TransductionAntithrombotic TherapyPlatelet ActivationPlatelet AggregationPlatelet FunctionPlatelet PhysiologySodium-glucose Cotransporter 2 InhibitorsNitric OxidePlatelet Aggregation InhibitionPlatelet Function ModulationPlatelet InhibitionPlatelet MetabolismSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
35
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text
Medicine, Nephrology, Pharmacology +17
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text